Drug‐likeness evaluation and inhibitory mechanism of the emodin derivative on cardiac fibrosis based on metastasis‐associated protein 3
The emodin derivative shows improved drug-likeness and potent inhibition of cardiac fibrosis by targeting E2F1, disrupting its pro-fibrotic function, restoring MTA3 expression and halting fibrosis progression. This advances emodin derivative's potential as a clinical therapy for cardiac fibrosis and provides insights into its anti-fibrotic mechanisms.
Authors
- Denis Baranenko (ORCID: https://orcid.org/0000-0002-9284-4379)
- Weihong Lu (ORCID: https://orcid.org/0000-0002-1051-4043)
- Zhixia Wang (ORCID: https://orcid.org/0000-0002-5242-3668)
- Xiuxiu Sun (ORCID: https://orcid.org/0000-0001-7188-8316)
- Heng Liu (ORCID: https://orcid.org/0000-0001-6683-1462)
- Weina Han (ORCID: https://orcid.org/0000-0001-7241-1608)
- Han Lou
- Runze Li (ORCID: https://orcid.org/0000-0002-0154-2202)
- Run Xu
- Xinxin Dong (ORCID: https://orcid.org/0000-0003-1944-3445)
- Xue Bai (ORCID: https://orcid.org/0009-0001-0831-1706)
- Ange Hu
- Dan Xiao
Institutions
- Harbin Medical University (CN)
- ITMO University (RU)
- Harbin Institute of Technology (CN)
- Hainan University (CN)
- The Fourth People's Hospital (CN)
Publication Details
- Journal
- British Journal of Pharmacology
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1111/bph.70012
- Citations
- 4
- Primary Topic
- Signaling Pathways in Disease
- Type
- article
- Field-Weighted Citation Impact
- 3.22
Funders
- National Natural Science Foundation of China